特鲁利夫大麻
估值 各估值倍数与自身5年区间的对比
同业对比 Drug Manufacturers - Specialty & Generic
| 公司 | 市值 | 市盈率(TTM)i | 市净率i | 股息率i |
|---|---|---|---|---|
| 特鲁利夫大麻 (TRLV) | 1.93B | -4.05 | 2.51 | 0.00% |
| Takeda Pharmaceutical (TAK) | 62.84B | -59.43 | 1.31 | 3.04% |
| Teva Pharmaceutical Industries (TEVA) | 48.40B | 69.17 | 6.24 | 0.00% |
| Haleon (HLN) | 44.55B | 21.06 | 2.05 | 1.88% |
| Zoetis (ZTS) | 32.80B | 12.95 | 10.42 | 2.60% |
| United Therapeutics (UTHR) | 22.87B | 19.10 | 3.57 | 0.00% |
StockVane 追踪范围内同行业的其他公司。
Morningstar
当前股价低于晨星合理价值估算25.8%。
合理价值
Trulieve Cannabis Corp earns a 4-star quantitative star rating, illustrating our stance that this share class offers a somewhat attractive opportunity for investors. The stock currently trades at a 15% discount to our quantitative fair value estimate of $12.59 per share; however, caution is warranted due to this estimate's high uncertainty rating. We require the price/fair value ratio to move a certain amount before the star rating can change. This stability-enhancing buffer is in effect for this stock.
The company's balance sheet strengthens our quantitative valuation. Low leverage mitigates financial risk, potentially boosting a firm's value. Reflecting the firm's leverage is its current ratio of 5.9, which sits in the top 10% compared with peers globally. We have little concern about this company's ability to cover near-term obligations, thanks to its relatively high current ratio; this could be a compelling signal during times of distress, which contributes to our view that shares are undervalued.
Conversely, the company's lack of profitability is potentially concerning. Companies with low profitability are often less resilient in recessions and are likely to generate weaker future cash flows for shareholders. The firm's earnings yield of 1.1%, a core component of profitability, falls in the bottom 40% globally. The earnings generated by the company relative to its share price is concerning, which, despite our favorable price/fair value ratio, is a negative attribute.
In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance bodes well for future returns in light of other contributors to our model.
经济护城河
With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.
作者:Quantitative Equity Report
报价时间 2026-10-16 19:30:04 · 仅供参考,不构成投资建议,也未考虑您的具体情况。
特鲁利夫大麻 讨论区 0 条评论